Liraglutide may help overweight and obese adults lose weight safely and effectively
2015-03-07
(Press-News.org) San Diego, CA-- Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes. Patients who achieved that weight loss showed improvements on a number of health markers, compared to those who lost less, and the patients on liraglutide showed greater improvement on measures of blood sugar control and blood pressure. The results will be presented Saturday, March 7, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
"The US Food and Drug Administration recently approved liraglutide 3.0 mg for the treatment of obesity as an adjunct to diet and exercise," said lead study author Patrick M. O'Neil, PhD, director of the Weight Management Center and professor in the Department of Psychiatry and Behavioral Sciences of the Medical University of South Carolina in Charleston. "In the US, 3.0 mg of liraglutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity."
The worldwide increase in the prevalence of obesity is a serious public health issue, with rates of obesity having nearly doubled since 1980. In the United States, roughly 80 million people - around 35% of adults - have obesity.
To examine the efficacy and safety of liraglutide for weight management, Dr. O'Neil and his colleagues conducted the double-blind, placebo-controlled multinational SCALE Obesity and Prediabetes trial over 56 weeks. They randomized 2,487 overweight or obese study participants to treatment with liraglutide 3.0 mg and 1,244 participants to placebo, in combination with diet and exercise. Their average age was 45 years and 79% were female. The participants had comorbidities, such as prediabetes, hypertension and dyslipidemia, but people with diabetes were excluded from the trial.
Participants who lost 5% or more of their body weight after 56 weeks were called "responders."
After 56 weeks, 63.2% of participants on liraglutide were considered "responders," compared with 27.1% of those on placebo, and responders in both the drug and placebo groups achieved clinically meaningful improvements.
Fasting plasma glucose decreased most among the responders in the liraglutide group followed by the non-responders in the liraglutide group. Waist circumference, systolic blood pressure, and 36-Item Short Form Health Survey (SF-36) decreased most among the responders in the liraglutide group followed by the responders in the placebo group.
The rates of adverse events were largely similar in responders and non-responders.
"Many people with obesity are unaware of its severity and its implications for their health. Losing 5% to 10% of their weight can give them significant health benefits, including improvements in blood glucose levels, blood pressure, cholesterol levels and obstructive sleep apnea. The nature of this disease is complex and maintaining weight loss can be challenging. Multiple treatment options are needed to help people with obesity lose weight, keep it off, and improve their health," Dr. O'Neil said.
Novo Nordisk funded this study.
INFORMATION:
Founded in 1916, the Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society's membership consists of over 18,000 scientists, physicians, educators, nurses and students in 122 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2015-03-07
San Diego, CA-- A new study has confirmed that transgender youth often have mental health problems and that their depression and anxiety improve greatly with recognition and treatment of gender dysphoria. The results will be presented Saturday at The Endocrine Society's 97th annual meeting in San Diego.
"Youth with gender incongruence or dysphoria need a comprehensive, multidisciplinary approach to care," said principal investigator Maja Marinkovic, MD, a pediatric endocrinologist and Medical Director of the Gender Management Clinic at Rady Children's Hospital-San Diego, ...
2015-03-07
San Diego, CA-- A fetus exposed to tobacco smoke may be at increased risk for diabetes in adulthood, a new study of adult daughters finds. The results will be presented in a poster Saturday, March 7, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Women whose parents smoked during pregnancy had increased risk of diabetes mellitus independent of known risk factors, adding to the evidence that prenatal environmental chemical exposures can contribute to adult diabetes mellitus.
"From a public health perspective, reduced fetal environmental tobacco ...
2015-03-07
San Diego, CA--In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual meeting of the Endocrine Society, in San Diego.
"We found that over two years, men with declining serum concentrations of testosterone were more likely to develop a significant decrease in their sexual activity and sexual desire. In older men, decreased sexual activity and desire may be a cause - not an effect - of low circulating ...
2015-03-07
San Diego, CA--Why men have more heart disease than premenopausal women has been unclear, but a new study shows that the sex hormones testosterone and estrogen alter cardiovascular risk factors in a way that raises a man's risk of heart disease. Results of the study will be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.
Men have higher testosterone and lower estrogen levels than premenopausal women. Therefore, doctors have suspected that testosterone may promote cardiovascular disease or that estrogen may protect against it, or both, according ...
2015-03-07
San Diego, CA-- Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego.
"Recognition of this association between breast and thyroid cancer should prompt vigilant screening for thyroid cancer among breast cancer survivors," said lead investigator Jennifer Hong Kuo, MD, assistant professor of surgery at Columbia University, New ...
2015-03-07
San Diego, CA-- An experimental drug causes loss of weight and fat in mice, a new study has found. The study results will be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
Known as GC-1, the drug reportedly speeds up metabolism, or burning off, of fat cells.
"GC-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat," said study author Kevin Phillips, PhD, a researcher at Houston Methodist ...
2015-03-07
San Diego, CA-- A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
"Current diagnostic procedures for thyroid cancer often yield uncertain results, leading to recurrent medical procedures and a large number of thyroid surgeries performed unnecessarily," said the study's senior investigator, Donald Bodenner, MD, PhD, chief of endocrine oncology at the University of ...
2015-03-06
People with anorexia nervosa and with body dysmorphic disorder have similar abnormalities in their brains that affect their ability to process visual information, a new UCLA study reveals.
People with anorexia have such an intense fear of gaining weight that they starve themselves even when they are dangerously thin. Body dysmorphic disorder is a psychiatric condition characterized by an obsessive preoccupation with a perceived flaw in physical appearance.
The researchers found that people with both disorders had abnormal activity in the visual cortex of the brain during ...
2015-03-06
San Diego, CA -- A tooth enamel abnormality in children, molar incisor hypomineralization (MIH), may result from exposure to the industrial chemical bisphenol A (BPA), authors of a new study conclude after finding similar damage to the dental enamel of rats that received BPA. The study results will be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
"Human enamel defects may be used as an early marker of exposure to BPA and similar-acting endocrine disruptors," Babajko said.
BPA is an endocrine disruptor, or hormone-altering chemical, that ...
2015-03-06
Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine. For nearly three decades, immunologists' efforts to develop a herpes vaccine have centered on exploiting a single protein found on the virus's outer surface that is known to elicit robust production of antibodies. Breaking from this approach, Howard Hughes Medical Institute (HHMI) scientists at Albert Einstein College of Medicine have created a genetic mutant lacking that protein. The result is a powerfully effective vaccine against herpes viruses.
"We have ...
LAST 30 PRESS RELEASES:
[Press-News.org] Liraglutide may help overweight and obese adults lose weight safely and effectively
